基于网络药理学探讨中药复方益糖康从脾论治糖尿病的机制

Discussion on Mechanism of Chinese Medicine Compound Yitangkang(复方益糖康)Treating Diabetes from Spleen Based on Network Pharmacology

目的基于网络药理学研究中药复方益糖康从脾论治糖尿病的分子机制。方法应用中药系统药理学技术平台(TCMSP)数据库检索中药复方益糖康中脾经药物红参、黄芪、黄连、黄精、茯苓、白术6味中药的有效成分,并进行靶点预测。通过DisGeNET、TTD数据库检索糖尿病相关的疾病靶点,将中药靶点与疾病靶点进行交集,筛选得到共同靶蛋白。应用STRING平台构建蛋白-蛋白相互作用(PPI)网络模型。使用Cytoscape软件对该网络进行拓扑学分析得到核心关键靶点,并对核心靶点基因进行GO-BP生物功能富集分析,应用DAVID平台对其进行KEGG通路分析。结果经数据库分析共筛选出红参有效活性成分3个,黄芪有效活性成分16个,黄精有效活性成分11个,黄连有效活性成分10个,茯苓有效活性成分14个,白术有效活性成分5个和635个潜在作用靶点,其中与糖尿病共有靶点103个,通过对共同靶点的拓扑分析,筛选出32个核心关键蛋白。经GO-BP富集分析,发现中药复方益糖康可能通过保护调节能量代谢、MAP激酶的活性、改善血管功能、调控神经营养素受体信号传导、以及调节脂质、磷脂、活性氧的代谢过程等生物功能发挥对从脾论治糖尿病的治疗作用。通过KEGG通路分析,得到5条与糖尿病相关通路,即VEFG信号通路、MAPK信号通路、mTOR信号通路、胰岛素信号通路以及2型糖尿病信号通路。结论从多角度探索了中药复方益糖康从脾论治糖尿病的分子机制,为其临床应用提供了科学依据。

Objective To study the molecular mechanism of Yitangkang(复方益糖康) treating diabetes mellitus from spleen based on network pharmacology. Methods The Traditional Chinese medicine system pharmacology technology platform(TCMSP) database was used to search the active constituents[Hongshen(Ginseng Radix Et Rhizoma Rubra),Huangqi(Astragali Radix),Huanglian(Coptidis Rhizoma),Huangjing(Polygonati Rhizoma),Fuling(Poria),Baizhu(Atractylodis Macrocephalae Rhizoma)] of Compound Yitangkang. Through DisGeNET and TTD databases, the target of diabetes-related diseases was searched, and the target of traditional Chinese medicine was intersected with the target of the disease to screen a common target protein. A protein-protein interaction(PPI) network model was constructed by using the STRING platform. Cytoscape software was used to analyze the network to obtain the core key targets, and the core target genes were analyzed by GO-BP biological function enrichment. The KEGG pathway was analyzed by DAVID platform. Results A total of effective active ingredients of Compound Yitangkang were screened by database analysis, including 3 of Hongshen(Ginseng Radix Et Rhizoma Rubra), 16 of Huangqi(Astragali Radix), 11 of Huangjing(Polygonati Rhizoma), 10 of Huanglian(Coptidis Rhizoma), 14 of Fuling(Poria), 5 of Baizhu(Atractylodis Macrocephalae Rhizoma) and 635 potential targets. A total of 103 targets were shared with diabetes, and 32 core key proteins were screened by topological analysis of common targets. After GO-BP enrichment analysis, it was found that Compound Yitangkang may regulate energy metabolism and MAP kinase activity, improve vascular function, regulate neurotrophin receptor signaling, and regulate lipid, phospholipid and reactive oxygen species metabolism. Such biological functions play a therapeutic role in diabetes. Through the KEGG pathway analysis, five pathways related to diabetes, namely, VEFG signaling pathway, MAPK signaling pathway, mTOR signaling pathway, insulin signaling pathway and type II diabetes signaling pathway were obtained. Conclusion The molecular mechanism of treating diabetes mellitus from spleen by Yitangkang is explored from various angles, providing a scientific basis for its clinical application.